The cell-selective permeability of a retrievable microporous device encapsulating human therapeutic cells and implanted in the intraperitoneal space of mice provides long-term protection to the transplanted cells by dampening foreign-body responses and preventing the immune rejection of the graft.
References
Desai, T. & Shea, L. D. Nat. Rev. Drug Discov. 16, 338–350 (2017).
Henry, R. R. et al. Diabetes 67 (Suppl. 1), 138–OR (2018).
Bose, S. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-0538-5 (2020).
Salehi, S. & Reed, E. F. Curr. Opin. Organ Transplant. 20, 446–453 (2015).
Anderson, J. M., Rodriguez, A. & Chang, D. T. Semin. Immunol. 20, 86–100 (2008).
An, D. et al. Proc. Natl Acad. Sci USA 115, E263–E272 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors are employed by Novo Nordisk, hold shares in the company and are involved in the company’s stem cell research and development.
Rights and permissions
About this article
Cite this article
Coppieters, K., Winkel, L. & von Herrath, M. Long-term viability through selective permeability. Nat Biomed Eng 4, 763–764 (2020). https://doi.org/10.1038/s41551-020-0602-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-020-0602-1
- Springer Nature Limited
This article is cited by
-
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus
BioDrugs (2023)
-
Current and future therapies for type 1 diabetes
Diabetologia (2021)